Navigation Links
Omeros Reports Additional Positive Results from OMS824 Program
Date:9/12/2013

SEATTLE, Sept. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development. With these data and the previously announced encouraging results from the OMS824 positron emission tomography (PET) clinical trial, Omeros is advancing OMS824 into Phase 2 clinical programs. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.

The OMS824 Phase 1 clinical trial included single- and multiple-dose escalation studies that enrolled 100 healthy male subjects: 60 subjects received a single dose of OMS824, 24 subjects received multiple doses for seven to 10 days, and 16 subjects received placebo. The data announced today are at the highest multiple-dose level administered and, at this dose, OMS824 was well tolerated and the only apparent drug-related adverse events were mild. Almost all adverse events were self-limiting, resolving during the 10-day dosing period. In May of this year, Omeros reported that a lower dose evaluated in an ongoing PET clinical trial demonstrated target engagement greater than had previously been reported for any PDE10 inhibitor (an average of approximately 50-percent and a maximum of approximately 70-percent engagement) without the dose-limiting side effects seen with other PDE10 inhibitors. Pharmacokinetic data at the high dose announced today showed an approximately two-fold increase in plasma concentration over that of the dose used in the earlier-reported PET trial. This same high dose l
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Omeros Corporation Reports Second Quarter 2013 Financial Results
5. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Omeros Submits New Drug Application to U.S. FDA for OMS302
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
9. Omeros Corporation Reports First Quarter 2013 Financial Results
10. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)... Influenza will affect as many as 200,000 people ... United States as high as 49,000 people.  The ... from person to person in respiratory droplets of coughs and ... death, but kills much fewer people each year than the ... fluids including sweat, saliva, blood and other bodily fluids. The ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... 2 Meeting with the FDA for the Fabry Program and Initiation ... ... Quarter, CRANBURY, N.J., Aug. 7 ... pharmacological chaperones for the treatment of human,genetic diseases, today announced financial results ...
... 7 The American Association of Diabetes,Educators ... conducted by Harris,Interactive highlighting communication between people ... healthcare providers. According to the,survey results, 33 ... of,dread relating to insulin injections (eight percent ...
Cached Medicine Technology:Amicus Therapeutics Announces Second Quarter 2008 Financial Results 2Amicus Therapeutics Announces Second Quarter 2008 Financial Results 3Amicus Therapeutics Announces Second Quarter 2008 Financial Results 4Amicus Therapeutics Announces Second Quarter 2008 Financial Results 5Amicus Therapeutics Announces Second Quarter 2008 Financial Results 6Amicus Therapeutics Announces Second Quarter 2008 Financial Results 7Amicus Therapeutics Announces Second Quarter 2008 Financial Results 8Amicus Therapeutics Announces Second Quarter 2008 Financial Results 9Amicus Therapeutics Announces Second Quarter 2008 Financial Results 10Amicus Therapeutics Announces Second Quarter 2008 Financial Results 11Amicus Therapeutics Announces Second Quarter 2008 Financial Results 12New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 2New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 3New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 4
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) ... for NBC News in Liberia has cleared the virus ... Nebraska Medical Center in Omaha, where he had been treated for ... test confirmed by the U.S. Centers for Disease Control and Prevention ... NBC News reported Tuesday night. "Recovering from Ebola ...
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... , , , CARLSBAD, Calif., ... the leader in antisense therapeutics, today announced that management will present ... Conference on Tuesday, August 11, 2009, at 1:00 p.m. ET at ... audio webcast of the presentation will be available on the "Investors ...
... , , SPRING, ... pleased to advise the nutrition and investing community that its flagship ... corporate activities, are easily accessible by simply Googling Cholesterade(R). , ... recent updates on Go Healthy and/or its products, we are confident ...
... , , , , ... high-performance sports water , is targeting ... of major sporting events throughout the late summer and fall. ... cellular hydration in the most demanding environments, from professional sporting events ...
... ... UK have brought every major video conference endpoint manufacturer together for the ultimate in ... altogether under one roof and connect with MCU, Gateway, Firewall, Streaming & Recording infrastructure ... ...
... ... Web site with resources for people with disabilities coincides with Americans with Disabilities Act,s ... ... Americans with Disabilities Act, the U.S. Department of Labor has re-named and re-launched its ...
... , , WASHINGTON, ... announced that they have been chosen as the exclusive ... improvement program, called the IC3 Program(R) (Improving Continuous Cardiac ... Record (EHR) interfacing and data extraction process beginning with ...
Cached Medicine News:Health News:Go Healthy's Marquis Product Cholesterade(R) at Your Fingertips on Google 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 3Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 2Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 3Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 4Health News:Disability.gov Adds Social Media Tools, Disability Resources and a New Design to Complement Information from 22 Federal Agencies 2Health News:Disability.gov Adds Social Media Tools, Disability Resources and a New Design to Complement Information from 22 Federal Agencies 3Health News:Featherstone Informatics Group, Inc. Named Exclusive Vendor for the American College of Cardiology's Practice-Based Data Registry Program 2
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle....
Grooved roller, on which knife oscillates....
Medicine Products: